Cardinal Health (CAH) Gets a Buy from Morgan Stanley

Morgan Stanley analyst Erin Wright reiterated a Buy rating on Cardinal Health today and set a price target of $255.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Wright covers the Healthcare sector, focusing on stocks such as Molina Healthcare, UnitedHealth, and Henry Schein. According to TipRanks, Wright has an average return of 14.5% and a 63.50% success rate on recommended stocks.

In addition to Morgan Stanley, Cardinal Health also received a Buy from TD Cowen’s Charles Rhyee in a report issued on May 1. However, yesterday, J.P. Morgan maintained a Hold rating on Cardinal Health (NYSE: CAH).

Based on Cardinal Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $60.94 billion and a net profit of $399 million. In comparison, last year the company earned a revenue of $54.88 billion and had a net profit of $506 million

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CAH in relation to earlier this year. Most recently, in February 2026, Aaron E Alt, the CFO of CAH sold 4,242.00 shares for a total of $947,556.06.